AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022
New Real-World Evidence Highlights AMGEVITA® Utilization, Treatment Satisfaction and Persistence in European Patients
New Data From First-in-Class Treatment TAVNEOS®, Evaluating Renal Function Among Adults Living With Severe Active ANCA-Associated Vasculitis
THOUSAND OAKS, Calif., Nov. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022.
Among 25 abstracts, noteworthy presentations will include real-world evidence for AMGEVITA®* (adalimumab), underscoring treatment satisfaction and persistence in German patients with rheumatic diseases. Additional data will highlight utilization in European patients with moderate to severe rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.